Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Colchicine Reduces Inflammatory Markers Associated with Metabolic Syndrome

Key clinical point: Colchicine reduced markers of inflammation in patients with metabolic syndrome.

Major finding: C-reactive protein dropped by 2.8 mg/L in the active group but increased slightly in the placebo group.

Study details: A randomized, placebo-controlled study comprising 40 patients

Disclosures: The study was supported by the Intramural Research Program of the Eunice Kennedy Shriver National Institute of Child Health and Human Development and by the National Institutes of Health. None of the authors reported any disclosures or conflicts of interest relating to this study.

Citation:

Yanovski JA et al. Diabetes Obes Metab. 2019 Mar 14. doi: 10.1111/dom.13702.